They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?
Anthem’s American Resident Project provides an opportunity for a select few up-and-coming doctors (the program calls them fellows) to write one blog post a month on a subject of their choice. In turn, this can lead to a host of networking and educational opportunities.
They may still wear white coats and use stethoscopes. But these younger doctors—they’re different.
With their tech savvy and willingness to work in groups, they could shake up the status quo of American health care, although they are perceived as being weaker on some of the “old school” virtues like a good bedside manner, according to a survey conducted by MediMedia Research.
Editorial Advisory Board Member Richard Gabriel Stefanacci, DO, talks about the different points of view among him and his 85-year-old physician father, Richard George Stefanacci, and his 20-year-old daughter, Morgan Stefanacci, who’s contemplating a career in health care. Is there a doctor in the house?
Nearly 15% of the population cares for a loved one. They spend an average of 24 hours a week on caregiving, and nearly 60% have to tackle complex medical tasks, such as giving injections. They need training, and many argue that they also deserve financial reimbursement. Some health plans agree.
Long-term care is expensive for all concerned—those getting it, their family, caregivers, and taxpayers. And the situation is only expected to get worse as the American population ages.
Researchers conclude that linaclotide is less expensive and just as effective as lubiprostone for treating chronic idiopathic constipation. Total direct costs were $946 per linaclotide treated patient, and $1,015 per patient treated with lubiprostone. “The results of this study are intended to provide useful information for determining effective treatment options…”
What regulators will be focusing on as they scrutinize the Anthem–Cigna and Aetna–Humana deals.